Proteon plans Ph III for elastase in kidney disease surgery
This article was originally published in Scrip
Executive Summary
Proteon Therapeutics is planning to move its recombinant human elastase into Phase III trials after announcing positive results from a Phase II trial of the product, PRT-201, in chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF) in preparation for hemodialysis.